1. Home
  2. GERN vs SHCO Comparison

GERN vs SHCO Comparison

Compare GERN & SHCO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • GERN
  • SHCO
  • Stock Information
  • Founded
  • GERN 1990
  • SHCO 1995
  • Country
  • GERN United States
  • SHCO United States
  • Employees
  • GERN N/A
  • SHCO N/A
  • Industry
  • GERN Biotechnology: Pharmaceutical Preparations
  • SHCO Hotels/Resorts
  • Sector
  • GERN Health Care
  • SHCO Consumer Discretionary
  • Exchange
  • GERN Nasdaq
  • SHCO Nasdaq
  • Market Cap
  • GERN 1.5B
  • SHCO 1.4B
  • IPO Year
  • GERN 1996
  • SHCO 2021
  • Fundamental
  • Price
  • GERN $1.56
  • SHCO $6.27
  • Analyst Decision
  • GERN Buy
  • SHCO Strong Buy
  • Analyst Count
  • GERN 11
  • SHCO 3
  • Target Price
  • GERN $5.80
  • SHCO $7.00
  • AVG Volume (30 Days)
  • GERN 14.9M
  • SHCO 472.5K
  • Earning Date
  • GERN 05-01-2025
  • SHCO 05-09-2025
  • Dividend Yield
  • GERN N/A
  • SHCO N/A
  • EPS Growth
  • GERN N/A
  • SHCO N/A
  • EPS
  • GERN N/A
  • SHCO N/A
  • Revenue
  • GERN $76,994,000.00
  • SHCO $1,198,989,000.00
  • Revenue This Year
  • GERN $208.83
  • SHCO $9.52
  • Revenue Next Year
  • GERN $57.49
  • SHCO $7.40
  • P/E Ratio
  • GERN N/A
  • SHCO N/A
  • Revenue Growth
  • GERN 32386.92
  • SHCO 8.45
  • 52 Week Low
  • GERN $1.46
  • SHCO $4.43
  • 52 Week High
  • GERN $5.34
  • SHCO $8.47
  • Technical
  • Relative Strength Index (RSI)
  • GERN 30.82
  • SHCO 42.79
  • Support Level
  • GERN $1.63
  • SHCO $6.69
  • Resistance Level
  • GERN $1.89
  • SHCO $6.84
  • Average True Range (ATR)
  • GERN 0.11
  • SHCO 0.45
  • MACD
  • GERN 0.03
  • SHCO 0.02
  • Stochastic Oscillator
  • GERN 6.94
  • SHCO 51.61

About GERN Geron Corporation

Geron Corp is a clinical-stage biopharmaceutical company focused on the research and development of cancer treatments. The company's drug in development, Imelstat, is being tested for the treatment of myelodysplastic syndromes, which are disorders of the blood, and myelofibrosis, which is a rare blood cancer affecting bone marrow. The company earns revenue through collaboration agreements, milestones, royalties, and licensing arrangements. Geron possesses various rights to this drug. The company operates as a single segment being, the development of therapeutic products for oncology.

About SHCO Soho House & Co Inc.

Soho House & Co Inc is a membership platform of physical and digital spaces that connects a vibrant, diverse group of members from across the world. The members use the platform to work, socialize, connect, create and flourish all over the world. It offers lease agreement Houses, hotels, restaurants, studios, spas, and other properties. The company's reportable segments are; United Kingdom, North America, and Europe and Rest of the World. Majority of its revenue is generated from the North America segment which encompasses its operating units in North America, including; Soho Houses, stand-alone U.S. restaurants and the Willows Inn in Palm Springs, Soho Friends, and the management fees from Soho Beach House Canouan.

Share on Social Networks: